遗传性铁过载加重MDS病理生理,药物性铁限制在临床前研究中改善MDS
本研究利用FPNC326S突变诱导铁过载和vamifeport药物抑制铁输出蛋白FPN实现铁限制,在MDS小鼠模型中分析铁过载与铁限制对疾病病理生理的影响。铁过载加重而铁限制减轻氧化应激、DNA损伤及造血干祖细胞死亡,vamifeport改善贫血并显著提高生存率。vamifeport联合luspatercept在改善贫血和髓系偏向上优于单药治疗。
要点
- FPNC326S突变诱导的铁过载未显著改善晚期红系成熟,但加重HSPC氧化应激、DNA损伤和细胞死亡。
- vamifeport介导的铁限制通过减少红系祖细胞氧化应激和凋亡改善MDS小鼠贫血及红细胞成熟。
- vamifeport联合luspatercept在改善贫血和髓系偏向上优于单药,并具叠加获益。
核心结论
- 临床前模型首次证明铁在非输血依赖MDS中起病理作用,药物性FPN抑制揭示早期预防铁毒性的治疗潜力。
- 铁过载加重而铁限制减轻MDS小鼠的贫血、氧化应激、DNA损伤、HSPC死亡及髓系偏向。
研究设计与样本
- 在MDS小鼠模型中采用互补方法:通过C326S突变(FPNC326S)遗传性激活铁输出蛋白FPN诱导铁过载,以及药理学抑制FPN(vamifeport)实现铁限制。
主要发现
- FPNC326S诱导的铁过载未显著改善晚期红系成熟,而vamifeport介导的铁限制通过减少红系祖细胞氧化应激和凋亡改善MDS小鼠贫血及红细胞成熟。
- 铁过载加重而铁限制减轻HSPC中活性氧形成、DNA损伤和细胞死亡,导致细胞存活和质量改变。
- 铁过载加重而铁限制减轻骨髓髓系祖细胞扩增和循环未成熟髓系原始细胞所指示的髓系偏向。
- vamifeport治疗改善MDS小鼠贫血并显著提高生存率。
- vamifeport联合红系成熟剂luspatercept在改善贫血和髓系偏向上优于单药治疗,并在MDS中提供叠加获益。
临床怎么用
- 作者认为,药理学FPN抑制的有益效果揭示了在非输血依赖MDS中早期预防铁毒性的治疗潜力。
- 作者指出,铁在非输血依赖MDS中起病理作用,输血性铁过载可能加重该作用,依据为FPNC326SMDS模型中的观察。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although iron overload is a common feature in myelodysplastic syndromes (MDS), it remains unclear how iron excess is detrimental for disease pathophysiology. Taking advantage of complementary approaches, we analyzed the impact of iron overload and restriction achieved through genetic activation of ferroportin (FPN) via the C326S mutation (FPNC326S) and pharmacologic inhibition (vamifeport) of the iron exporter FPN, respectively, in a MDS mouse model. Although FPNC326S-induced iron overload did not significantly improve the late stages of erythroid maturation, vamifeport-mediated iron restriction ameliorated anemia and red blood cell maturation in MDS mice, through the reduction of oxidative stress and apoptosis in erythroid progenitors. Iron overload aggravated, and restriction alleviated, reactive oxygen species formation, DNA damage, and cell death in hematopoietic stem and progenitor cells (HSPCs), resulting in altered cell survival and quality. Finally, myeloid bias, indicated by expanded bone marrow myeloid progenitors and circulating immature myeloid blasts, was exacerbated by iron excess and attenuated by iron restriction. Overall, vamifeport treatment resulted in improved anemia and significant survival increment in MDS mice. Interestingly, the combined therapy with vamifeport and the erythroid maturation agent luspatercept has superior effect in improving anemia and myeloid bias as compared with single treatments and offers additive beneficial effects in MDS. Our results prove, to our knowledge, for the first time in a preclinical model, that iron plays a pathologic role in transfusion-independent MDS. This is likely aggravated by transfusional iron overload, as suggested by observations in the FPNC326SMDS model. Ultimately, the beneficial effects of pharmacologic FPN inhibition uncovers the therapeutic potential of early prevention of iron toxicity in transfusion-independent MDS.
引用
- Antypiuk A, Vance SZ, Sharma R, et al. Genetic iron overload aggravates, and pharmacological iron restriction improves, MDS pathophysiology in a preclinical study. Blood. 2025. PMID: 39437711. doi:10.1182/blood.2024026135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。